Response Time and BRAF Status Factor Into IO Selection for Melanoma
In the DREAMseq trial [NCT02224781]…at the time that trial was accruing, it…was very slow to accrue, and one of the criticisms at the time was that not everyone felt comfortable using ipilimumab/nivolumab, and everyone begged Dr Atkins to consider a third arm where there was an option of single agent, and he said, ‘I’m not going to do it,’
During a Case-Based Roundtable event, Thach‑Giao Truong, MD, discussed how data from the CheckMate‑067 and RELATIVITY‑047 trials affect their choice of therapy for metastatic melanoma in the first article of a 2‑part series.
The BRAF mutation status influences first‑line choice; patients with BRAF mutation tend to benefit more from ipilimumab/nivolumab, whereas patients without BRAF mutation may be directed to nivolumab/relatlimab.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research